全文获取类型
收费全文 | 7026篇 |
免费 | 355篇 |
国内免费 | 213篇 |
出版年
2024年 | 8篇 |
2023年 | 81篇 |
2022年 | 133篇 |
2021年 | 170篇 |
2020年 | 141篇 |
2019年 | 160篇 |
2018年 | 136篇 |
2017年 | 108篇 |
2016年 | 119篇 |
2015年 | 215篇 |
2014年 | 466篇 |
2013年 | 467篇 |
2012年 | 415篇 |
2011年 | 528篇 |
2010年 | 352篇 |
2009年 | 303篇 |
2008年 | 363篇 |
2007年 | 310篇 |
2006年 | 324篇 |
2005年 | 259篇 |
2004年 | 274篇 |
2003年 | 227篇 |
2002年 | 183篇 |
2001年 | 137篇 |
2000年 | 133篇 |
1999年 | 118篇 |
1998年 | 145篇 |
1997年 | 107篇 |
1996年 | 125篇 |
1995年 | 140篇 |
1994年 | 137篇 |
1993年 | 103篇 |
1992年 | 77篇 |
1991年 | 86篇 |
1990年 | 79篇 |
1989年 | 51篇 |
1988年 | 46篇 |
1987年 | 47篇 |
1986年 | 27篇 |
1985年 | 55篇 |
1984年 | 60篇 |
1983年 | 37篇 |
1982年 | 50篇 |
1981年 | 25篇 |
1980年 | 21篇 |
1979年 | 16篇 |
1978年 | 7篇 |
1977年 | 10篇 |
1976年 | 6篇 |
1975年 | 3篇 |
排序方式: 共有7594条查询结果,搜索用时 31 毫秒
991.
前期的相关研究发现mRNA二级结构中存在对蛋白质折叠速率的重要影响因素.而mRNA二级结构中普遍存在着各种复杂的环结构,这些环结构是否对蛋白质折叠速率也有重要的影响呢?不同的环结构对蛋白质折叠速率的影响是否相同呢?基于此想法,建立了一个包含mRNA内部环、发夹环、膨胀环和多分支环等环结构信息和相应蛋白质折叠速率的数据库.对于数据库中的每一个蛋白质,计算了mRNA二级结构中各种环结构碱基含量、配对碱基含量及单链碱基含量等参量,分析了各参量与相应蛋白质折叠速率的相关性.结果显示,各种环结构碱基含量与蛋白质折叠速率均呈极显著或显著正相关.说明mRNA环结构对蛋白质折叠速率有重要的影响.进一步,把蛋白质按照不同折叠类型或不同二级结构类型分组后,对每一组蛋白质重复上述的分析工作.结果表明,对不同类蛋白质,mRNA的各种环结构对其相应蛋白质折叠速率的影响存在着显著差异.上述研究将为进一步开展有关mRNA和蛋白质折叠速率的研究奠定理论基础. 相似文献
992.
Tomasz Kolenda Weronika Przybyła Marta Kapałczyńska Anna Teresiak Maria Zajączkowska Renata Bliźniak Katarzyna M. Lamperska 《Reports of Practical Oncology and Radiotherapy》2018,23(3):143-153
Head and neck squamous cell carcinomas (HNSCC) are in a group of cancers that are the most resistant to treatment. The survival rate of HNSCC patients has been still very low since last 20 years. The existence of relationship between oncogenic and surrounding cells is probably the reason for a poor response to treatment. Fibroblasts are an important element of tumor stroma which increases tumor cells ability to proliferate. Another highly resistance, tumorigenic and metastatic cell population in tumor microenvironment are cancer initiating cells (CICs). The population of cancer initiating cells can be found regardless of differentiation status of cancer and they seem to be crucial for HNSCC development.In this review, we describe the current state of knowledge about HNSCC biological and physiological tumor microenvironment. 相似文献
993.
Alaa Kashmiry Rothwelle Tate Giuliana Rotondo Jillian Davidson Dino Rotondo 《Biochimica et Biophysica Acta (BBA)/Molecular and Cell Biology of Lipids》2018,1863(10):1297-1304
Prostaglandin E2 (PGE2) is responsible for inflammatory symptoms. However, PGE2 also suppresses pro-inflammatory cytokine production. There are at least 4 subtypes of PGE2 receptors, EP1–EP4, but it is unclear which of these specifically control cytokine production. The aim of this study was to determine which of the different receptors, EP1R–EP4R modulate production of tumor necrosis factor-α (TNF-α) in human monocytic cells.Human blood, or the human monocytic cell line THP-1 were stimulated with LPS. The actions of PGE2, alongside selective agonists of EP1–EP4 receptors, were assessed on LPS-induced TNF-α, IL-1β and IL-10 release. The expression profiles of EP2R and EP4R in monocytes and THP-1 cells were characterised by RT-qPCR. In addition, the production of cytokines was evaluated following knockdown of the receptors using siRNA and over-expression of the receptors by transfection with constructs.PGE2 and also EP2 and EP4 agonists (but not EP1 or EP3 agonists) suppressed TNF-α production in blood and THP-1 cells. LPS also up regulated expression of EP2R and EP4R but not EP1 or EP3. siRNA for either EP2R or EP4R reversed the suppressive actions of PGE2 on cytokine production and overexpression of EP2R and EP4R enhanced the suppressive actions of PGE2.This indicates that PGE2 suppression of TNF-α by human monocytic cells occurs via EP2R and EP4R expression. However EP4Rs also control their own expression and that of EP2 whereas the EP2R does not affect EP4R expression. This implies that EP4 receptors have an important master role in controlling inflammatory responses. 相似文献
994.
995.
996.
997.
998.
999.
Toshihiko Tashima 《Bioorganic & medicinal chemistry letters》2018,28(18):3015-3024
Cancer is one of the major causes of death globally. The current treatment options are insufficient, leading to unmet medical needs in cancer treatment. Off-target side effects, multidrug resistance, selective distribution to cancerous tissues, and cell membrane permeation of anti-cancer agents are critical problems to overcome. There is a method to solve these problems by using receptor-mediated endocytosis (RME). It is well known that proteins such as integrin, HER2, EGFR, or other cancer biomarkers are specifically overexpressed on the surface of target cancer cells. By taking advantage of such specific receptors, payloads can be transported into cells through endocytosis using a conjugate composed of the corresponding ligands connected to the payloads by an appropriate linker. After RME, the payloads released by endosomal escape into the cytoplasm can exhibit the cytotoxic activity against cancer cells. Cell-penetrating peptides (CPPs), tumor-homing peptides (THPs), and monoclonal antibodies (mAbs) are utilized as ligands in this system. Antibody drug conjugates (ADCs) based on RME have already been used to cure cancer. In addition to the canonical conjugate method, nanocarriers for spontaneous accumulation in cancer tissue due to enhanced permeability and retention (EPR) effect are extensively used. In this review, I introduce the possibilities and advantages of drug design and development based on RME for the treatment of cancer. 相似文献
1000.
Afsaneh Sadremomtaz Kamran Mansouri Golnaz Alemzadeh Majid Safa Ahmadreza Esmaeili Rastaghi S. Mohsen Asghari 《Biochimica et Biophysica Acta (BBA)/General Subjects》2018,1862(12):2688-2700